Precision Radiotherapy Enabled by Molecular MRI
ConditionBrain Cancer
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18+
SponsorSidney Kimmel Comprehensive Cancer Center at Johns Hopkins
About this trial
This is a research study to determine if a novel molecular magnetic resonance imaging (MRI) technique, called amide proton transfer (APT) imaging, is useful in identifying the most aggressive areas of tumor needed for radiotherapy of brain tumors.
Eligibility criteria
Qualifiers
Histologic confirmation of glioblastoma or grade 4 astrocytoma
Age >18
KPS at least 60
leukocytes >3,000/mcL
Disqualifiers
Patients who are unable to receive MRIs will be excluded from the study.
Patients may not be receiving any other investigational cancer treatment agents at the time of enrollment.
Patients may not have previously been treated with an overlapping course of radiotherapy to the brain.
Uncontrolled intercurrent illness including, but not limited to ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.
Trial design
Treatments tested in this trial
- Amide proton transfer radiotherapy
- Standard radiotherapy
Treatment groups
20 Participants
are divided into 2 treatment groupsSponsors and collaborators
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Lead sponsor
The Ben & Catherine Ivy Foundation
Collaborator
Source ClinicalTrials.gov